

**Supplementary Table S1: Clinicopathologic characteristics of patients with HCC**

	Collection #1 (n = 42)	Collection #2 (n = 43)
Mean age, years	55.5	62.3
Sex ratio (M/F)	2.3	5.1
HCV infection	17	7
HBV infection	4	10
Alcohol abuse	5	2
Hemochromatosis	2	1
Metabolic syndrome	7	6
Combined viral infection and alcohol consumption	4	7
Combined metabolic syndrome and alcohol consumption	0	4
Other etiologies	3	6
Mean tumour size, mm	45	43
Advanced fibrosis/cirrhosis in adjacent liver	30	26

**Supplementary Table S2: Pharmacological inhibitors**

<b>Inhibitors</b>	<b>Targets</b>	<b>Providers</b>
LY294002	PI3K	Sigma-Aldrich, St. Louis, MO
U0126	MEK	Cell Signaling Technology, Inc, Danvers, MA
SP600125	JNK	MERCK SERONO SAS, Lyon, France
gefitinib	EGFR	Tocris Bioscience, Bristol, UK
AKT inhibitor VIII	AKT	MERCK Millipore SAS, Molsheim, France
rapamycin	mTOR	Cell Signaling Technology, Inc, Danvers, MA
STAT3 inhibitor III, WP1066	STAT3	MERCK Millipore SAS, Molsheim, France,

**Supplementary Table S3: Antibodies for Western blot and immunofluorescence**

<b>Antibodies</b>	<b>References</b>	<b>Providers</b>
IR (4B8)	3025	Cell Signaling Technology, Inc., Danvers, MA
pAKT (D9E)	4060	Cell Signaling Technology, Inc., Danvers, MA
pERK (E-4)	sc-7383	Santa Cruz Biotechnology, Inc., Santa Cruz, CA
CUGBP1 (3B1)	sc-20003	Santa Cruz Biotechnology, Inc., Santa Cruz, CA
hnRNPH (N-16)	sc-10042	Santa Cruz Biotechnology, Inc., Santa Cruz, CA
hnRNPA1 (4B10)	sc-32301	Santa Cruz Biotechnology, Inc., Santa Cruz, CA
hnRNPA2B1	Ab6102	Abcam, Cambridge, UK
hnRNPF (3H4)	Ab6095	Abcam, Cambridge, UK
SF2/ASF (96)	sc-33652	Santa Cruz Biotechnology, Inc., Santa Cruz, CA
Srp20 (7B4)	sc-13510	Santa Cruz Biotechnology, Inc., Santa Cruz, CA
$\beta$ -actin	A5441	Sigma Aldrich, St. Louis, MO

**Supplementary Table S4: Primer pairs for qualitative and quantitative PCR**

	<b>Targets</b>	<b>Forward</b>	<b>Reverse</b>
<b>Human primers</b>	IR-tot (both isoforms)	5' CTGGTCTCCACCATTTCGAGT 3'	5' CAAGGGACCTGCGTTTCCG 3'
	IR-A	5' CTGGTCTCCACCATTTCGAGT 3'	5' CGAGATGGCCTGGGGACG 3'
	IR-B	5' CTGGTCTCCACCATTTCGAGT 3'	5' CCTCGGCACCAGTGCCTG 3'
	CUGBP-1	5' CCAAAACCCGCCTCAGAGC 3'	5' AGGCCATCAGGTCCCCGC 3'
	hnRNP-H	5' GTGCAGTTTGCTTCACAGGA 3'	5' CCAGCTCCTGCCAATGCT 3'
	hnRNP-A2B1	5' ACCAGGGTGGGGGCTACGG 3'	5' CCCACTTCTCCACTGCC 3'
	hnRNP-A1	5' TGGAGGTGGTGGAACTACA 3'	5' TAGCTACTGCTGCTGCTGGA 3'
	hnRNPF	5' CATCCAGAAGTGTCTCCAC 3'	5' GAGAGGAAGTTCTGCACGTC 3'
	SF2/ASF	5' GAGTTCGAGGACCCGCGAG 3'	5' CGGCCGCTTCGAGGAAACTC 3'
	HPRT	5' TAATTGGTGGAGATGATCTCTCAAC 3'	5' TGCCTGACCAAGGAAAGC 3'
	IR-A/IR-B (semi-quantitative)	5' ACTCTCAGATCCTGAAGGAG 3'	5' GACTCCTGTTCACCAC 3'
<b>Rat Primers</b>	IR-tot (both isoforms)	5' CCCGAGTGCCCGTCTGGCTA 3'	5' GCCAGGTTGTTGCCCCCTCG 3'
	IR-A	5' CACAATCAGAGTGAGTATGAC 3'	5' TCGGGATGGCCTGGGAACA 3'
	IR-B	5' CACAATCAGAGTGAGTATGAC 3'	5' TGTCTCAGCACCATTGCCT 3'
	CUGBP-1	5' ATGAAACCCGCGGACAGTGA 3'	5' GCACAACCTCTGCTCAAGCC 3'
	hnRNP-H	5' GAGATTGGACCTGATGGCAG 3'	5' GACAAACCCATGCCTCTAG 3'
	hnRNP-A2B1	5' GGTGGAGGACCTGGATATGG 3'	5' GGTCTCCCATGTTCTCTGC 3'
	hnRNP-A1	5' GCTCTCATCATCCTACCGTC 3'	5' CAGTCGGTGTGAGTGTCCCC 3'
	hnRNPF	5' ACAGAAGGCATCTGTGGTGG 3'	5' CCACTCTGCCTGCCTTCTC 3'
	SF2/ASF	5' CGAGATGGCACTGGTGTGC 3'	5' GGCTTCTGCTACGACTACGG 3'
HPRT	5' AGGACCTCTCGAAGTGT 3'	5' ATCCCTGAAGTGCTCATTATAG 3'	

**Supplementary Table S5: Correlations between IR-A and splicing factor mRNA levels in human HCC tumours**

	Collection #1		Collection #2	
	rho	<i>P</i>	rho	<i>P</i>
CUGBP1	0.722	< 0.0001	0.757	< 0.0001
hnRNPH	0.727	< 0.0001	0.747	< 0.0001
hnRNPA1	0.676	< 0.0001	0.651	< 0.0001
hnRNPA2B1	0.756	< 0.0001	0.750	< 0.0001
SF2/ASF	0.610	< 0.0001	0.640	< 0.0001

Spearman rho correlation coefficient and *p* values are presented.